Product Description
NUC-7738 is a ProTide transformation of 3'-deoxyadenosine (3'-dA), also known as cordycepin. 3’-dA has demonstrated potent anti-cancer activity in non-clinical studies, but has not been successfully developed as a anti-cancer agent due to its rapid breakdown by adenosine deaminase (ADA). It is a nucleoside analog. (Sourced from: https://www.nucana.com/nuc7738.html)
Mechanisms of Action: RNA Synthetase Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nucana
Company Location: EDINBURGH X0 EH12 9DT
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NuTide:701 | P2 |
Recruiting |
Lymphoma |
2024-06-01 |